Business Wire

IonQ Unveils New Enterprise-Grade Quantum OS and Hybrid Services Suite

2.12.2024 22:05:00 CET | Business Wire | Press release

Share

Full stack development approach drives enterprise-grade capabilities, enabling improved quantum functionality for commercial applicationsIonQ Quantum OS drives an average reduction of over 50 percent in on-system classical overhead, improving time to solution for quantum workloads

IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the launch of its quantum operating system, now called IonQ Quantum OS, and a collection of new capabilities named IonQ Hybrid Services suite. These technologies will greatly advance performance and utility of quantum computing for enterprise customers.

IonQ Quantum OS is a nearly ground-up rewrite of IonQ’s original quantum operating system. Designed and built with a flexible and modular architecture, it is designed to scale and adapt with IonQ’s hybrid quantum computing ecosystem and power IonQ’s current and future flagship quantum computers, including IonQ Forte and IonQ Forte Enterprise.

Designed for improved performance, IonQ Quantum OS dramatically improves time-to-solution, including:

  • An average reduction of over 50 percent in on-system classical overhead (compared to identical workloads run on IonQ Forte before the improvements were deployed).
  • An 85 percent reduction in cloud and network overhead of workloads submitted through the IonQ Cloud.
  • Up to 100x improved accuracy in an expanded error mitigation and compilation suite.
  • Enhanced calibration, automation, and control software and firmware to optimize qubit and gate performance and adjust for systemic drifts, resulting in better algorithmic performance.

IonQ Quantum OS also offers enterprise-grade security through improved observability and enhanced interoperability across on-premise hardware and software solutions. These improvements provide customers with new options for securely integrating quantum computing into their stack. IonQ Quantum OS has been running commercial workloads on IonQ Forte since summer 2024 and will soon be operational in controlling IonQ Forte Enterprise as it comes online in IonQ’s Basel, Switzerland data center.

“We designed our Quantum OS not only to address the complex demands of today’s enterprises but to scale seamlessly as their needs evolve,” said Peter Chapman, President and CEO of IonQ. “Our goal is to empower enterprise customers to unlock new possibilities and drive innovation with quantum computing.”

Showcased as an early preview with NVIDIA at SuperCompute 2024, IonQ’s new Hybrid Services suite is designed to enable seamless development and deployment of hybrid workloads that integrate IonQ quantum computers with high-performance classical resources over the cloud. This suite introduces significant advancements to enhance the speed, performance, and usability of quantum workloads, including:

  • The Workload Management & Solver Service, a quantum developer toolkit that offers capabilities to efficiently move hybrid workloads to the cloud. This service features a quantum function and hybrid solver designed to help developers simplify the process of manually building circuits and iterative algorithms by packaging them into portable workloads to be executed and enhanced based on their needs.
  • A new scheduling feature, Sessions, built on top of IonQ’s Fair Share scheduling engine, is designed to streamline provisioning of QPU time so that iterative and resource-intensive workflows run with minimal wait and interruption. Sessions also provides expanded support for offerings from IonQ’s cloud partners, including Amazon Braket Hybrid Jobs and Azure Quantum Sessions.
  • The all-new IonQ SDK allows for seamless, simple, and reliable integration with IonQ Quantum Cloud API and IonQ Hybrid Services.

IonQ Hybrid Services suite is already accelerating the development of real-world, commercial quantum hybrid applications with customers. IonQ recently worked with Oak Ridge National Laboratory (ORNL) to implement a beta version of Hybrid Services to support the development of a NISQ-friendly quantum algorithm, which accelerates time-to-solution for hard optimization problems.

To learn more about IonQ and its latest system news and business developments, visit https://ionq.com.

About IonQ

IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words ”will,” “expect,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the expected benefits of IonQ’s quantum operating system and hybrid services suite, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, IonQ’s quantum computing capabilities and plans, the commercial relevance and advantages of applications, and the performance, scalability, accessibility, ease of use, capacity, power, speed, latency, quality, and reliability of IonQ’s quantum computing offerings. IonQ’s quantum computing capabilities and plans, improved efficiency and speed of quantum workloads and algorithms run on IonQ’s quantum computers, and the scalability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; and events that may impact the security, quality and reliability of IonQ’s technology. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241202941767/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye